Clinical Trial Update: Safety Extension Study of TRO19622 in ALS [Phase 2, Phase 3]

View source ↗

Summary

Safety extension study of TRO19622 (olesoxime) in amyotrophic lateral sclerosis has completed Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• TRO19622

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Amyotrophic Lateral Sclerosis | Phase 2, Phase 3 | Status: COMPLETED